Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
CIT CIT Group Inc
NXPI NXP Semiconductors NV
PRTK Paratek Pharmaceuticals Inc
VTR Ventas Inc
GBIM Globeimmune Inc
SCKT Socket Mobile Inc
BK Bank of New York Mellon Corp
BAC Bank of America Corp
AACG ATA Creativity Global
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Price
Delayed
$38.25
Day's Change
0.30 (0.79%)
Bid
--
Ask
--
B/A Size
--
Day's High
38.85
Day's Low
38.03
Volume
(Heavy Day)

Today's volume of 15,219,156 shares is on pace to be much greater than PFE's 10-day average volume of 21,868,196 shares.

15,219,156

Company Profile

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Valuation Ratios

Price/Earnings (TTM)
15.44x
Price/Sales (TTM)
4.29x
Price/Book (MRQ)
3.28x
Price/Cash Flow (TTM)
10.94x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

September 2020
Current Month
45.2M
Previous Month
42.8M
Percent of Float
0.81%
Days to Cover
2.5166 Days

Share Information

PFE is in a share class of common stock
Float
5.6B
Shares Outstanding
5.6B
Institutions Holding Shares
3,052
69.22%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Albert BourlaChmn.
  • John D. YoungPres.
  • Frank A. D'AmelioCFO
  • Angela HwangCorp.Exec.
  • Dawn Rogers

Address

Insider Trading

During the most recent quarter, 13K shares were bought, and 191K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.